MLNT News and Press, Melinta Therapeutics Inc - Ordinary Shares

MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purch...

The bidding competition for Tetraphase Pharmaceuticals (NASDAQ: TTPH ) is not over yet. La Jolla Pharmaceutical (NASDAQ: LJPC ) has submitted an unsolicited bid of $43.0M in cash plus an additional $16.0 payable under contingent value rights (CVRs). More news on: Tetraphase Pharmaceutica...

Emerging victorious in a bidding joust with AcelRx Pharmaceuticals (NASDAQ: ACRX ), Melinta Therapeutics (NASDAQ: MLNT ) enters into a definitive merger agreement with Tetraphase Pharmaceuticals (NASDAQ: TTPH ) under which it will acquire the company for $39M in cash plus an additional $16...

Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio  MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotic...

AcelRx Pharmaceuticals (NASDAQ: ACRX ) announces that it does not intend to revise its latest cash-and-stock bid for Tetraphase Pharmaceuticals (NASDAQ: TTPH ) and expects the termination of their previously announced merger agreement since the latter's board deemed a competing offer f...

Signaling its determination to close the deal amid rival offers, AcelRx Pharmaceuticals ( ACRX -4.0% ) has increased its bid for Tetraphase Pharmaceuticals ( TTPH -8.3% ) to $30M in cash and stock plus an additional $14.5M in cash payable under a contingent value right (CVR). More news...

The board of Tetraphase Pharmaceuticals (NASDAQ: TTPH ) has determined that the recent acquisition offer  of up to $39.5M in upfront cash and a potential CVR payout from Melinta Therapeutics (NASDAQ: MLNT ) is superior to the previously-agreed-to all-stock deal valued at ~$14.4M fr...

Tetraphase Pharmaceuticals (NASDAQ: TTPH ) discloses that it received an unsolicited bid yesterday from Melinta Therapeutics (NASDAQ: MLNT ) for $27.0M in cash plus an additional $12.5M payable under a contingent value right (CVR). More news on: Tetraphase Pharmaceuticals, Inc., Melinta ...

Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company Continues Operations with No Anticipated Disruption to Product Supply or Support MO...

Antibiotics maker, Paratek Pharmaceuticals ( PRTK ), has struggled to hold onto gains in 2019. The has been a recent setback in the clinic but success on the funding front, both of which are worth discussing and the first focus of this article. Secondly, I look forward to a potential catalys...